Chemomab Therapeutics Ltd. (CMMB) Stock Forecast
CMMB analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $5.00 average of analyst targets
- Upside to target
- +295.3% from the latest close
- Next earnings
- —
- 52-week range
- $1.19 – $3.40
CMMB analyst ratings
1 analystsNumber of analysts at each rating.
CMMB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CMMB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | $0.00 | $0.00 | −$0.00 | +100.0% | 1 |
| Current fiscal year (2026) | −$0.02 | −$0.02 | −$0.02 | −$0.02 | −11.1% | 1 |
| Next fiscal year (2027) | −$0.03 | −$0.03 | −$0.03 | −$0.02 | −50.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CMMB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
CMMB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CMMB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.01 | −$0.01 | $0.00 | $0.00 | $0.00 | −100.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.02 | −$0.02 | −$0.02 | −$0.02 | −$0.02 | 0.0% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.04 | −$0.04 | −$0.03 | −$0.03 | −$0.03 | −25.0% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CMMB earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CMMB beat in 8 of 11.
What analysts expect from CMMB
1 analysts cover Chemomab Therapeutics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.00, 295.3% above the latest close of $1.26. Analysts expect earnings of −$0.02 per share for 2026, −11.1% from a year earlier. For 2027 the average estimate is −$0.03 per share. Chemomab Therapeutics beat the EPS estimate in 8 of the last 11 quarters.
Related: CMMB income statement, CMMB key metrics, CMMB chart. See the CMMB stock overview for the latest quote and news.
CMMB forecast FAQ
What is Chemomab Therapeutics's price target?
The average analyst price target for Chemomab Therapeutics is $5.00, 295.3% above the latest close of $1.26.
Is Chemomab Therapeutics a buy, hold or sell?
Of 1 analysts covering Chemomab Therapeutics, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Chemomab Therapeutics's EPS forecast?
Analysts forecast −$0.02 per share for 2026 (range −$0.02 to −$0.02); for 2027 the estimate is −$0.03.
Does Chemomab Therapeutics usually beat earnings estimates?
Chemomab Therapeutics reported EPS at or above the analyst estimate in 8 of the last 11 quarters.